~~<i id='7001D34EAB'><strike id='7001D34EAB'><tt id='7001D34EAB'><pre id='7001D34EAB'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

fashion

author：hotspot 2025-09-06 01:58:50 - browse：42295

For a decade, leading academic institutes and their associated companies fought a bruising, headline-grabbing fight over who held patent rights to CRISPR-Cas9, the revolutionary genome editing tool.

Editas Medicine, the winner of that battle in the U.S., will now cash in.

Vertex Pharmaceuticals and Editas announced Wednesday that Vertex will pay Editas $50 million, along with a series of annual payments through 2034, in exchange for rights to use CRISPR-Cas9 in Casgevy, the sickle cell therapy approved last week.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How to save PrEP access — and even expand it
Next article： Brain injuries and the importance of a second opinion

focus

explore

focus

entertainment

explore

knowledge

Adobe’Tistheseason—openenrollmentseason,thatis.SincebeforetheNov.1 starttotheannualopenenrollmentper

WSS

Leukemia patients are helped by Syndax's new type of therapy

STAT Event – Decoding Clinical Trials: Venture Capitalists Talk Early Biotech R&D

After sickle

FDA needs staff influx to meet gene therapy needs, Marks says

Prime Medicine says its gene editing passes test in monkeys

Medicare must police algorithms in Medicare Advantage, Dems say

hotspot

fashion

focus

The cancer drug shortage isn’t new — and neither are the solutions

What causes an itch? Researchers may have solved the mystery

Hollywood unions extend contract negotiations for actors

After Sarepta trial failure, Duchenne families brace for more debate

Psychedelics group wrestles with new pharma identity

Medicare proceeds with plan to claw back hospital funds

In age of alternative facts, a scholarly course on calling out crap

Roche to buy Carmot Therapeutics, developer of obesity drugs

Wildfire smoke exposes gaps in outdoor worker protections

Key Senate panel to consider PBM, drug pricing reform package

explore

Brain injuries and the importance of a second opinion

CMS should re

What is microchimerism and how does it affect maternal health?

STAT letters to the editor on burnt

Americans' trust in science, scientist continues decline: Report

Medicare proceeds with plan to claw back hospital funds

focus

entertainment

explore

knowledge